Dr. Reddy’s Expands Access to Immunotherapy for Rare Head and Neck Cancer
JOHANNESBURG, South Africa / HYDERABAD, India, Aug. 3, 2026 Dr. Reddy’s Laboratories South Africa announced the registration of an...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
JOHANNESBURG, South Africa / HYDERABAD, India, Aug. 3, 2026 Dr. Reddy’s Laboratories South Africa announced the registration of an...
HYDERABAD, India, Aug. 1, 2026 Dr. Reddy’s Laboratories Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
Boston & Bedford, Massachusetts, August 3, 2026 Curium and Lantheus Holdings, Inc. have entered into a definitive merger agreement...
Boston, Massachusetts, August 3, 2026 Haemonetics Corporation has announced the publication of a major real-world clinical study providing additional...
SUNNYVALE, Calif., Aug. 3, 2026 Ceribell, Inc. has secured a significant reimbursement milestone after the U.S. Centers for Medicare...
ROCKVILLE, Md. & RICHMOND, Va., Aug. 3, 2026 Supernus Pharmaceuticals and Indivior Pharmaceuticals announced they have entered into a...
ZUG, Switzerland, Aug. 3, 2026 Oculis announced that the U.S. Food and Drug Administration (FDA) has provided positive pre-Investigational...
IRVINE, Calif., July 31, 2026 enVVeno Medical Corporation reported its second quarter 2026 financial results, highlighting significant progress toward...
NANJING, China, July 30, 2026 Leads Biolabs announced that its Phase II clinical trial evaluating Opamtistomig (LBL-024), a proprietary...
BAD HOMBURG, Germany, July 31, 2026 Fresenius Kabi, an operating company of Fresenius, announced that both the U.S. Food...
